TRANEXAMIC VERSUS KLIGMAN IN MELASMA TREATMENT

Khaled Gharib; Amany Nassar; kFathi Essnusi Elkasah; Mohamed Hussein AbouHadeed

doi:10.36602/mmsj/2023.n9.04

TRANEXAMIC VERSUS KLIGMAN IN MELASMA TREATMENT

Authors

Khaled Gharib Dermatology Department, Faculty of Medicine, Zagazig University, Egypt
Amany Nassar Dermatology Department, Faculty of Medicine, Zagazig University, Egypt
kFathi Essnusi Elkasah DepartmentDermatologyandVenereology,facultyofMedicineSirte University, Libya
Mohamed Hussein AbouHadeed Department of Dermatology and Venereology, National Research Centre,Giza, Egypt

DOI:

https://doi.org/10.36602/mmsj/2023.n9.04

Keywords:

Melasma, Tranexamic acid, Chitosan microparticles, MASI score

Abstract

Melasma is a common dermatological condition that may presents a great therapeutic
challenge to treat. The specific aim of the present study was to evaluate the efficacy and
safety of topical tranexamic Acid (TA 3 %) loaded chitosan microparticles (TA-CsMPs)
as compared with modified Kligman’s formula. A total 24 females with melasma in our
nonrandomized comparison study were classified into 2 groups. Group (I) females advised
to apply topical 3 % TA-Cs microgel twice daily, while group (II) was received Kligman
regimen once daily at night. A modified Melasma Area Severity Index (m-MASI) score
was used to evaluate patients clinically once weekly for 6 weeks and followed up for 3
more months after treatment completion. Dermal type of melasma, with a lateral or centrofacial pattern of distribution and Fitzpatrick type III was found mostly in patients. The mMASI score was significantly lower in comparison to the baseline in both investigated
groups. Beside the adverse reaction as redness, irritation, or burning associated with topical
Kligman formula, TA-CsMPs regimen has superior efficacy and safety in melasma
treatment. Taken together, our current outcomes demonstrated that topical 3% TA-CsMPs
is an innovative, effective, and could be a potentially promising safe alternative with good
patient acceptance for melasma treatment.

Downloads

Published

24-06-2025

How to Cite

Khaled Gharib, Amany Nassar, kFathi Essnusi Elkasah, Mohamed Hussein AbouHadeed. TRANEXAMIC VERSUS KLIGMAN IN MELASMA TREATMENT. mmsj [Internet]. 2025 Jun. 24 [cited 2026 Apr. 17];5(2):27-36. Available from: https://journals.misuratau.edu.ly/mmsj/ojs/index.php/mmsj/article/view/120

Download Citation

Issue

Vol. 5 No. 2 (2023)

Section

Original article

License

All articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, and redistribution for any purpose, including commercial ones, provided that proper credit is given to the original author and source, a link to the license is provided, and any changes made are indicated.